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Elsevier Taiwan LLC. Open access under CSummary Background: Malignant gastric outlet obstruction causes significant malnutrition
and morbidity. The implantation of a metallic stent is an alternative palliative treatment to
allow the intake of food in these patients.
Patients and Methods: Thirty-eight consecutive patients with malignant gastric outlet obstruc-
tion who had received an uncovered metallic stent placement in our department from April
2010 to April 2012 were enrolled for analysis. The mean follow-up time was 6.3 months. Food
intake, measured by the Gastric Outlet Obstruction Scoring System, complications, duration of
stent patency, and survival were evaluated.
Results: The technical and clinical success rates of the procedure were 100% and 94.7%,
respectively. The Gastric Outlet Obstruction Scoring System scores were significantly improved
at 1 day, 7 days, and 30 days after the implantation compared with those prior to the proce-
dure (p < 0.001). Aspiration pneumonia developed in two patients (5.2%) after the procedure.
One of these patients developed respiratory failure and died 3 days later. Stent dysfunction
developed in 11 of 38 patients (28.9%) during the follow-up period; one patient (2.6%) experi-
enced migration of the stent 38 days later due to resolution of the stricture; 10 patients
(26.3%) had stent restenosis. The median time of stent patency was 120 days. The presence
of peritoneal carcinomatosis when the procedure was carried out was a significantly poor pre-
dictive factor of stent patency [hazard ratio (HR) 7.9, p Z 0.039]. The median survival of theastroenterology, Department of Medicine, Taipei Veterans General Hospital, Number 201, Section 2,
tw (H.-C. Lin).
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2 K.-C. Lee et al.patients was 156 days. Poor performance status 3; HR 2.647, pZ 0.012) and nongastric can-
cer origin (HR 3.466, p Z 0.008) were associated with a significantly short survival time.
Conclusion: Metallic stent placement is an effective and relatively safe treatment for patients
with malignant gastric outlet obstruction.
Copyright ª 2014, The Gastroenterological Society of Taiwan and The Digestive Endoscopy So-
ciety of Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.Introduction
Malignant gastric outlet obstruction (MGOO), a late compli-
cation of advanced carcinoma of the stomach, duodenum,
periampulla, or pancreas, causes significant malnutrition
andmorbidity [1e3]. Persistent severe nausea and vomiting,
poor oral intake, and weight loss develop in these patients
[2]. These symptoms lead to dehydration, malnutrition,
cachexia, and a poor quality of life [4]. In addition, palliative
chemotherapy and radiotherapy cannot be administered
because of the patient’s poor clinical condition. These
patients usually die in a matter of weeks [1].
Self-expandable metallic stents have been suggested as
an alternative palliative treatment for MGOO in recent
years [5], especially in patients with an inoperable disease
[6]. This endoscopic treatment has the advantages of low
morbidity and mortality, early relief of symptoms, and no
need for general anesthesia [5]. In Taipei Veterans General
Hospital, Taipei, Taiwan, metallic stent placement started
to be performed in patients with inoperable MGOOs in April,
2010. The aim of this study was to evaluate the clinical
efficacy of stent placement in these patients.
Methods
Patients
We retrospectively reviewed 38 consecutive patients with
inoperable malignant carcinoma causing MGOO who
received metallic stent placement at Taipei Veterans
General Hospital between April 2010 and April 2012. MGOO
was confirmed by endoscopy or radiological studies. All pa-
tients had obstructive symptoms such as nausea, vomiting,
and poor oral intake. This study was approved by the insti-
tutional review board of Taipei Veterans General Hospital.
Stent placement procedure
Prior to the procedure, all patients received nothing by
mouth, with nasogastric tube drainage for at least 24 hours
to relieve symptoms of obstruction and decrease the risk of
aspiration.
All stents were deployed using a standard gastroscope
(JF-240/260, Olympus, Shinjuku-ku, Tokyo, Japan) under
fluoroscopic guidance without sedation. A guide wire
(0.89 mm  460 cm; Hydra Jagwire, Boston Scientific,
Natick, MA, USA) was introduced through the working
channel of the endoscope to more than 20 cm beyond the
site of obstruction. Water-soluble radiographic contrastwas injected to determine the length and location of the
stricture. The stent was chosen by the length of about an
additional 1e3 cm on either side of the stricture. The un-
covered stent (WallFlex Duodenal Stent; Boston Scientific
Corporation) was deployed under fluoroscopic guidance.
Radiological follow-up was performed to evaluate the
expansion and location of the metallic stent 1 day later.
Evaluation of the Gastric Outlet Obstruction
Scoring System
The primary outcome of the study was the improvement of
food intake. It was measured by the Gastric Outlet Obstruc-
tion Scoring System (GOOSS) score with 0 Z no oral intake,
1Z liquid diet, 2Z soft diet, and 3Z regular diet [2]. Based
on these data, clinical success was defined as a relief of
obstructive symptoms and improvement of oral intake. Other
outcomes, including technical success, complications, stent
dysfunction, and survival time, were also evaluated.
Definition of technical success and procedure-
related complications
Technical success of stent placement was defined as
adequate deployment and positioning of the stent. Com-
plications were both minor and major. Minor complications
were defined as those that were not life-threatening and
which did not require further aggressive treatment, such as
abdominal pain, nausea, and vomiting. Major complications
were defined as life-threatening or severe complications,
such as aspiration pneumonia, bleeding, perforation, stent
migration, and sepsis.
Data collection
Data were obtained from patients’ notes, radiology reports,
procedure notes, and telephone interviews. The collected
data included patient demographics, procedural charac-
teristics, complications, GOOSS score, duration of stent
patency, re-interventions, and survival time.
Statistical analysis
Continuous variables are presented as mean  standard de-
viation. The pre- and post-stent placement GOOSS scores
were analyzed using the Wilcoxon signed rank test. Univari-
ate analyses of survival time and the patency of the stent
were performed by KaplaneMeier analysis. Only variables
with p < 0.05 in univariate analysis were selected for
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sion models. Patients were recorded on the last date of
follow up, date of death, or development of in-stent reste-
nosis. The time to restenosis of stents and the survival curves
after stent placement in different groups were analyzed by
the log-rank test. Statistical significance was considered for
p < 0.05. All statistical analyses were performed using the
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Table 1 summarizes the characteristics of the enrolled pa-
tients. Of the 38 patients, 23 were men and 15 were
women, with a mean age of 70.2 years. Most patients
(76.3%) had a primary malignancy of gastric adenocarci-
noma. The sites of obstruction were the antrum in 11 pa-
tients, the pylorus in 29 patients, the duodenum in seven
patients, and the Billroth gastroduodenal anastomosis of
palliative subtotal gastrectomy in one patient. Among the
seven patients with the obstruction site at the duodenum,
two had an obstruction in the second portion of duodenum
due to pancreatic cancer, complicated with concomitant
biliary obstruction that was treated by percutaneous
transhepatic cholangial drainage the next day. Two patients
received radiotherapy and 18 patients received chemo-
therapy prior to the procedure. After stent placement, 16
patients received further chemotherapy and two patients
received further radiotherapy.Table 1 Patients’ demographic characteristics.
Sex
Male 23 (60.5)
Female 15 (39.5)
Age (y) 70.2  16.8a
BMI (kg/m2) 21.2  3.9
Performance status
0 8 (21.1)
1 8 (21.1)
2 7 (18.4)
3 11 (28.9)
4 4 (10.5)
Primary malignancy
Gastric cancer 29 (76.3)
Pancreatic cancer 4 (10.5)
Cholangiocarcinoma 5 (13.2)
Stage
IIIA 1 (2.6)
IIIB 1 (2.6)
IV 36 (94.8)
Site of obstruction
Antrum 11 (28.9)
Pylorus 19 (50.0)
Duodenum 7 (18.4)
Anastomosis 1 (2.6)
Prior radiation or chemotherapy 20 (52.6)
Data are expressed as n (%) or mean  SD.
BMI Z body mass index.
a Range, 31e100 years.Success of technique
The placement of the duodenal stents was uneventful in all
patients. The mean  standard deviation procedure time
was 27.2  8.8 minutes and the median procedure time was
25 minutes (range, 11e56 minutes).
Clinical success
Prior to stent placement, 26 patientswere unable to tolerate
intake by mouth and 11 patients tolerated only liquids.
Thirty-seven patients started oral intake within 1 day after
stent placement. One patient delayed oral intake until the
2nd day after the procedure due to abdominal pain. Another
patient had nausea and vomiting after the procedure and an
abdominal plain film radiograph showed a distended bowel
loop. Abdominal computed tomography was performed and
showed the ileus with a transitional zone around a splenic
flexure without evidence of pneumoperitoneum. After con-
servative treatment, his condition improved and he started
oral intake on the 3rd day after stent placement.
Overall, 36/38 patients (94.73%) had an improvement in
their levels of dietary intake. Two patients (5.27%) had no
improvement and none had a worse dietary status. The pre-
procedure GOOSS scores were 0.34  0.53. The GOOSS
scores were significantly increased the next day
(1.37  0.59) and achieved the maximum level on Day 7
(2.24  0.76), which was maintained on Day 30
(2.24  0.86) when compared with the basal scores
(p < 0.001). Table 2 gives the detailed GOOSS score dis-
tribution. However, the body mass index of the patients
had still decreased at the 30-day follow ups (initial
21.14  3.93 vs. 30-day 20.38  3.86, p Z 0.001) and the
plasma albumin levels remained unchanged (initial
3.01  0.46 vs. 30-day 2.94  0.52, p Z 0.209).
Complications and re-interventions
Table 3 gives the procedure-related complications. Two
patients (5.2%) had aspiration pneumonia. One of these two
patients recovered after treatment with antibiotics and
was discharged 7 days later; the other developed respira-
tory failure and died 3 days later because the patient had
requested no resuscitation. One patient (2.63%) had sepsis
and improved after empirical treatment with antibiotics.
One patient (2.63%) receiving chemotherapy had lateTable 2 Distribution of Gastric Outlet Obstruction Scoring
System (GOOSS) scores prior to and after placement of
metallic stent for gastric outlet obstruction.
GOOSS score Pre-procedure Postoperative
Day 1* Day 7* Day 30*
0 26 0 0 1
1 11 26 7 5
2 1 10 14 13
3 0 2 16 15
Data are expressed as n.
*p < 0.001 vs. pre-procedure group.
Figure 2 Time to restenosis after stent placement. Inci-
dence of recurrent obstructions recorded for patients still alive
after treatment.
Table 3 Complications related to the procedures.
Major complications n (%)
Aspiration pneumonia 2 (5.3)
Migration of stent 1 (2.6)
Sepsis 1 (2.6)
Minor complications
Abdominal pain 5 (13.2)
Nausea 3 (7.9)
Vomiting 5 (13.2)
4 K.-C. Lee et al.migration of their stent 38 days after the procedure.
Endoscopy showed that the stent was lodged at the third
portion of the duodenum, with an improvement of the
previous obstruction. The stent was smoothly removed via
over-tube and the patient had no obstructive symptoms by
the end of the follow-up period. Thirteen patients (34.21%)
experienced minor complications including abdominal pain
(5 patients), nausea (3 patients), and vomiting (5 patients);
these symptoms resolved within 1 week of conservative
treatment. No patient was observed to have secondary
biliary obstruction.
A total of 10 patients (26.31%) had recurrent obstruction
due to tumor ingrowth after stent placement (Fig. 1), but
only seven patients received further intervention. The
remaining three patients were treated with hospice care
because they were in the terminal stages of cancer. Four
patients received a new stent placement, one patient
received argon plasma coagulation ablation, one patient
underwent radiotherapy, and one patient had a naso-
jejunal (NJ) tube inserted. No further recurrent obstruc-
tion or endoscopic intervention was noted in these patients
until death or the end of follow-up.
The median duration for the patency of the stents was
120 days (range, 3e570 days). Fig. 2 shows the time to
restenosis after stent placement. On univariate analyses,Figure 1 Outcomes of patients with malignant gastric outlet
obstruction treated with metallic stent placement (n Z 38).
APC Z argon plasma coagulation; NJ Z nasojejunal.peritoneal carcinomatosis was the only significantly pre-
dictive factor of a shorter patency time (Table 4). The
patency times of patients with or without peritoneal
carcinomatosis were 123  93.24 days and 160.45  142.02
days, respectively (Fig. 3).
Survival
Thirty patients died during the follow-up period and the
median survival after the initial procedure was 156 days
(range, 3e570 days; Fig. 4). Using univariate and multi-
variate analyses, worse performance status (Eastern
Cooperative Oncology Group score 3) and cancer non-
gastric in origin were the significant risk factors of mortality
after stent placement (Table 5; Fig. 4).
Discussion
In this retrospective study, we found that the technical and
clinical success rates of stent placement were high and the
rate of major complications was low. Our results are com-
parable to those of other studies [6e9]. Stent placement
helped most patients to take in food and helped half of the
patients to receive further chemotherapy. At present,
commonly suggested treatments for MGOO are surgical
gastrojejunostomy (GJ) and stent placement [3]. GJ has
better long-term outcomes than stent placement, which
has better short-term outcomes [4]. Further, GJ has a
higher mortality rate, morbidity risk, prolonged hospital
stay, and delayed symptom relief compared with metallic
stents. Stent placement has a higher occlusion rate [4].
Therefore surgery is more suitable for patients in a better
condition and with a longer life expectancy, whereas a
Table 4 Univariate analysis of restenosis of metallic
stents.
Variable Univariate analysis
n Restenosis, n (%) p
Age (y) 0.436
<70 18 5 (27.8)
70 20 6 (30)
Sex 0.139
Male 23 6 (26.1)
Female 15 5 (33.3)
Tumor origin 0.220
Gastric cancer 29 11(37.9)
Nongastric cancer 9 0 (0)
Location of obstruction 0.462
Antrum 11 3 (27.3)
Pylorus 19 8 (42.1)
Duodenum 7 0 (0)
Length of stenosis (cm) 0.748
<5 10 2 (20)
5 12 2 (16.7)
Length of stent (cm) 0.147
<9 6 3 (50)
9 32 8 (25)
Previous RT 0.445
Yes 2 0 (0)
No 36 11 (30.6)
Post-procedure RT 0.619
Yes 1 0 (0)
No 37 11 (29.7)
Previous CT 0.902
Yes 23 6 (26.1)
No 15 5 (33.3)
Post-procedure CT 0.924
Yes 14 5 (35.7)
No 24 6 (25)
Peritoneal carcinomatosis 0.039
Yes 16 7 (43.8)
No 22 4 (18.2)
CT Z chemotherapy; RT Z radiotherapy.
Figure 3 Time to restenosis of stents in patients with or
without peritoneal carcinomatosis.
Stents in malignant gastric outlet obstruction 5metallic stent is better for those in a poorer condition. In
our study, none of our patients were suitable for surgery as
a result of advanced disease and its associated malnutrition
and poor performance status.
However, metallic stents are very expensive and many
patients cannot afford to use them. In such cases, tube
feeding can be considered [10]. The cost of an NJ tube is less
than that of a metallic stent. The fees for an NJ tube or
metallic stent in MGOO are not covered by the Bureau of Na-
tional Health Insurance in Taiwan. The price of an NJ tube and
metallic stent are around NT$3000 and NT$70,000 in Taiwan,
respectively. Although a higher dysfunction rate is associated
with an NJ tube, the use of an NJ tube could still provide
nutrition and achieve a similar survival rate to ametallic stent
[10]. Therefore thepatientswitha lowereconomic statusmay
choose an NJ tube placement to improve their nutrition.
Adequate selection and evaluation of patients with MGOO are
important when considering a palliative treatment modality
for these patients.The major procedure-related complication in our pa-
tients was aspiration pneumonia. One patient died, despite
adequate treatment. Much food is retained in the stomach
as a result of obstruction of the gastric outlet. These food
remnants are hard to remove by suction because they often
clog the orifices of nasogastric tubes or endoscopes.
Further, food aspiration can develop without any obvious
vomiting, particularly in those patients with poor mental or
performance status [11]. Aspiration could occur prior to or
during stent placement. Our patients were mostly in the
late stages of their disease with generalized cachexia and
were at a particularly high risk of developing aspiration
pneumonia. We need to fully explain this risk to patients
and take care with aspiration during stent placement.
Minor complications such as abdominal pain and vomit-
ing occurred in one-third of our patients after receiving the
procedures. Although these discomforts can be treated
conservatively, they may be associated with a longer stay in
hospital [4]. The pain and vomiting may be the result of
stimulation of the stent on the mucosa of the tumor. In
addition, long-term food remnants and poor gastric peri-
stalsis due to neoplastic involvement of the celiac plexus
also can lead to nausea and vomiting. In some cases, poor
gastric peristalsis may explain the lack of improvement in
the GOOSS score [5].
The common causes of malfunction of the stent after
placement are tumor ingrowth or outgrowth, stent migra-
tion, food impaction, and biliary obstruction [5]. Laasch et al
[12] reported that 20e25% of patients needed endoscopic re-
intervention after stent placement; this was 28.9% in our
series of patients. The reasons for re-intervention in our
patients were mostly tumor ingrowth causing stent reste-
nosis. In our current study, pre-existing peritoneal carcino-
matosis was the only significant risk factor for stent
restenosis. This implies that patients with peritoneal carci-
nomatosis might have a tendency for rapid tumor growth to
cause tumor ingrowth. By contrast, another study showed
Figure 4 Survival curves after stent placement in: (A) all patients with malignant gastric outlet obstruction; (B) patients with
cancer gastric or nongastric in origin; and (C) patients with high or low performance status. APC Z argon plasma coagulation;
NJ Z nasojejunal; PS Z performance status.
6 K.-C. Lee et al.that patients with MGOO and peritoneal carcinomatosis had
similar rates of early and late stent failure to those without
peritoneal carcinomatosis [13]. However, in that study, the
patients with carcinomatosis were younger and had more
favorable cancer types [13]. Post-stent chemotherapy did
not contribute significantly to stent patency in our patients,
although previous studies have shown that chemotherapy
after stent placement significantly increased the mainte-
nance of stent patency [14,15]. Different sample sizes, co-
horts, and chemotherapy regimens may explain this
discrepancy. In fact, one patient in our study who experi-
enced stent migration had an improvement in pyloric
obstruction after chemotherapy. Therefore further large
prospective trials are needed to evaluate which chemo-
therapy regimens, with or without radiotherapy, could
further prolong stent patency.Four of our patients received placement of another new
metallic stent. No further obstruction episodes occurred in
these patients prior to death or the end of follow-up. Jang
et al [16] showed that 19 of 20 patients (95%) had an
improvement in symptoms after a second stent placement,
but 1 of 20 patients (5%) developed duodenal perforation.
Gutzeit et al [17] found that half of their patients (3/6)
receiving a second stent developed stent dysfunction at 4
days, 47 days, and 240 days after the procedure, respec-
tively. Thus the occluded stent could be corrected by using a
stent-in-stent procedure. However, the safety and long-term
patency should be evaluated by further prospective studies.
The median survival after stent placement in our study
was 156 days compared with other studies that ranged from
7 days to 152 days [5,6,18e24]. We found that poor per-
formance status and cancer nongastric in origin were the
Table 5 Univariate and multivareate analysis of mortality.
Variable Univariate analysis Multivariate analysis
n Death (%) p HR 95% CI p
Age (y) 0.531
<70 18 77.8
70 20 80
Sex 0.055
Male 23 73.9
Female 15 86.7
Performance status 0.023 2.647 1.240e5.561 0.012
3 15 100
2 23 65.2
Tumor origin 0.010 3.466 1.381e8.698 0.008
Nongastric cancer 9 88.9
Gastric cancer 29 75.9
Stage 0.238
III 2 100
IV 36 28
Location of obstruction 0.082
Antrum 11 100
Pylorus 19 68.4
Duodenum 7 85.7
Length of stenosis (cm) 0.433
<5 10 80
5 12 66.7
Length of stent (cm) 0.814
<9 6 83.3
9 32 78.1
Previous RT 0.446
Yes 2 100
No 36 77.8
Post-procedure RT 0.511
Yes 1 100
No 37 78.4
Previous CT 0.713
Yes 23 78.3
No 15 80
Post-procedure CT 0.158
Yes 14 78.6
No 24 79.2
Peritoneal carcinomatosis 0.763
Yes 16 75
No 22 81.8
CI Z confidence interval; CT Z chemotherapy; HR Z hazard ratio; RT Z radiotherapy.
Stents in malignant gastric outlet obstruction 7significant predictors of shorter survival. Poor performance
status has been known to be associated with poor survival in
cancer patients [25]. Jemal et al [26] reported that patients
with a primary pancreatic carcinoma had a shorter survival
time than those with a gastric or duodenal carcinoma. Kim
et al [27] further showed that the survival rate was higher
in patients with gastric cancer than in patients with
pancreatic cancer with gastric outlet obstruction, but the
stent patency did not differ between the two groups. Our
data are in agreement with the study of Kim et al [27].
In conclusion, despite the limitations of this retrospec-
tive study and the small sample size, our study suggests
that metallic stent placement is an effective and relatively
safe method for patients with MGOO. Metallic stentplacement should be considered as a first line of treatment
in patients who are able to afford the related costs.Conflicts of interest
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